Sanofi-Aventis Sa (SNY) – Sanofi’s Hemophilia Candidate Goes Under Priority FDA Review
The FDA has accepted for priority review Sanofi SA’s SNY marketing application for efanesoctocog alfa (BIVV001) for hemophilia A, a rare bleeding disorder. The target action date for the FDA decision…